comparemela.com

Latest Breaking News On - Liver meeting - Page 1 : comparemela.com

HCV Treatment Disparities: What Contributes to Gaps in Health Care Access?

Elafibranor has significant, sustained treatment benefit in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
balticbusinessnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from balticbusinessnews.com Daily Mail and Mail on Sunday newspapers.

The latest research, treatments for biliary diseases presented at The Liver Meeting

The latest research, treatments for biliary diseases presented at The Liver Meeting
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.